This research develops pH-responsive biomaterials to deliver chemotherapy directly to glioblastoma cells in the brain. By releasing drugs in the presence of cancer while remaining closed around healthy tissue, the approach aims to improve treatment effectiveness, reduce harmful side effects, and ultimately enhance patients’ quality of life and survival.

This research develops nanoscale “smart package” delivery systems for PROTAC cancer drugs. Antibody nanogel conjugates selectively target cancer cells, enter them, and release therapeutic molecules while minimizing exposure to healthy tissue. The approach improves delivery efficiency and aims to reduce the severe side effects that often limit cancer treatment.